Compare Cassava Sciences Inc (FLNA) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Atlassian Corporation PLC — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Atlassian Corporation PLC trades at $93.58 (market cap $23.29B). The key difference: Atlassian Corporation PLC is far larger — about 438.3× Cassava Sciences Inc's market cap, and Atlassian Corporation PLC is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | TEAM | |
|---|---|---|
Market Cap | $53.14M | $23.29B |
Sector | Health | Technology |
52-Week High | $4.64 | $203.00 |
52-Week Low | $1.09 | $57.15 |
Enterprise Value | -$33.43M | $23.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
TEAM trades at $91.30, up 2.49% today, with a bullish technical outlook supported by moving averages and strong analyst consensus. Revenue growth accelerated to $5.22B in 2025, though net losses persist at -$257M. Recent news highlights AI-driven product launches and enterprise adoption, with the Service Collection surpassing $1B ARR. The stock remains below the consensus price target of $115.33, suggesting potential upside.
Outlook: Growth trajectory and AI integration offer upside, but profitability concerns and competitive pressures pose risks. Analyst sentiment is strongly bullish with no sell ratings. Investors should weigh robust revenue expansion against ongoing net losses and high valuation multiples like P/S of 3.89.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
